{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:45:39Z","timestamp":1762868739798,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the effects of the addition of single-dose GnRH agonist to the routine progestogens use for luteal phase support on IVF outcome as compared to progestogens only.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective case-control study on selected patients who underwent IVF treatment with fresh embryo transfer (ET) under Medically Assisted Conception Unit, University Kebangsaan Malaysia Medical Center for the period of June 2015\u2013June 2018. A higher dose of 0.2 mg subcutaneous Decapeptyl was administered 2 days before fresh ET concurrent with routine progestogen support. Patients with different luteal phase regimes, frozen embryo transfer and medical records with missing data were excluded. Their medical records were reviewed, and data analyzed. The pregnancy outcomes measured included biochemical pregnancy rates, clinical pregnancy rates, live birth rates and miscarriage rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 786 patients were analyzed. Four hundred forty-four patients were given luteal phase support with progestogens and GnRH agonist, whereas 342 patients served as control were given progestogens only. The study group showed higher biochemical pregnancy rate (47.7 vs. 44.4%,), clinical pregnancy rate (25.7 vs. 23.4%) and livebirth rate (24.3 vs. 22.2%), respectively but not statistically significant. The rate of miscarriage among the study group was lower (4.5% vs 9.4%) compared to the progestogen group alone. Nonetheless, the OHSS rate was slightly increased in the study group (4.5 vs. 3.5%) despite using a mild stimulation protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>New regime of GnRH agonist luteal support in addition to the standard progestogen support was found to be beneficial in overall IVF outcome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.760430","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T05:42:05Z","timestamp":1645076525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Single Dose Gonadotropin-Releasing Hormone Agonist Luteal Support in Fresh Embryo Transfer: Variation in Timing, Type, and Dosage"],"prefix":"10.3389","volume":"9","author":[{"given":"Muhammad Azrai","family":"Abu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jojinah Vindah","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Kadir","family":"Abdul Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Faizal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Hashim","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1210\/jc.2002-021953","article-title":"Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and gnrh antagonist cotreatment","volume":"88","author":"Beckers","year":"2003","journal-title":"<bold>J Clin Endocrinol Metab<\/bold>"},{"key":"B2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0015-0282(03)00663-0","article-title":"Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists","volume":"80","author":"Kolibianakis","year":"2003","journal-title":"Fertil Steril."},{"key":"B3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/oxfordjournals.humrep.a137871","article-title":"A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation","volume":"8","author":"Smitz","year":"1993","journal-title":"Hum Reprod."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/humrep\/17.9.2287","article-title":"Luteal phase support in infertility treatment: a meta-analysis of the randomized trials","volume":"17","author":"Pritts","year":"2002","journal-title":"Hum Reprod."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1093\/humrep\/del173","article-title":"Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles","volume":"21","author":"Tesarik","year":"2006","journal-title":"Hum Reprod."},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejogrb.2014.08.026","article-title":"The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial","volume":"182","author":"Yildiz","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/14647270701704768","article-title":"Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of < or=7 mm on day of egg retrieval","volume":"11","author":"Qublan","year":"2008","journal-title":"Hum Fertil."},{"key":"B8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1028-4559(09)60297-7","article-title":"Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection","volume":"48","author":"Razieh","year":"2009","journal-title":"Taiwan J Obstet Gynecol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.rbmo.2009.10.022","article-title":"Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?","volume":"20","author":"Ata","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"B10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/humrep\/dem421","article-title":"GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study","volume":"23","author":"Ata","year":"2008","journal-title":"Hum Reprod."},{"key":"B11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jcma.2014.07.001","article-title":"Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with basal follicle-stimulating hormone > 8 mIU\/mL or mature oocytes \u2264 3","volume":"77","author":"Kung","year":"2014","journal-title":"J Chin Med Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/humrep\/deh235","article-title":"Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation","volume":"19","author":"Tesarik","year":"2004","journal-title":"Hum Reprod."},{"key":"B13","first-page":"483","article-title":"Effects of single dose GnRH agonist as luteal support on pregnancy outcome in frozen-thawed embryo transfer cycles: an RCT","volume":"13","author":"Davar","year":"2015","journal-title":"Iran J Reprod Med."},{"key":"B14","first-page":"96","article-title":"Effect of administration of single dose GnRH agonist in luteal phase on outcome of ICSI-ET cycles in women with previous history of IVF\/ICSI failure: a randomized controlled trial","volume":"16","author":"Zafardoust","year":"2015","journal-title":"J Reprod Infertil."},{"key":"B15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fendo.2017.00124","article-title":"Impact of mid-luteal phase GnRH agonist administration on reproductive outcomes in GnRH agonist-triggered cycles: a randomized controlled trial","volume":"8","author":"Benmachiche","year":"2017","journal-title":"Front. Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/humrep\/deh830","article-title":"GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin*","volume":"20","author":"Pirard","year":"2005","journal-title":"Hum Reprod."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/humrep\/del072","article-title":"GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study","volume":"21","author":"Pirard","year":"2006","journal-title":"Hum Reprod."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/humrep\/16.8.1671","article-title":"Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF","volume":"16","author":"Fujii","year":"2001","journal-title":"Hum Reprod."},{"key":"B19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.rbmo.2009.04.001","article-title":"Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study","volume":"19","author":"Isik","year":"2009","journal-title":"Reprod Biomed Online."},{"key":"B20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.fertnstert.2016.10.011","article-title":"Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles","volume":"107","author":"Bar Hava","year":"2017","journal-title":"Fertil Steril"},{"key":"B21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.rbmo.2014.09.017","article-title":"GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study","volume":"30","author":"Aboulghar","year":"2015","journal-title":"Reprod Biomed Online."},{"key":"B22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1477-7827-8-30","article-title":"Combined analysis of endometrial thickness and pattern in predicting outcome of in vitro fertilization and embryo transfer: a retrospective cohort study","volume":"8","author":"Chen","year":"2010","journal-title":"Reprod Biol Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/09513590.2018.1563888","article-title":"The addition of single dose GnRH agonist to luteal phase support in artificial cycle frozen embryo transfer: a randomized clinical trial","volume":"35","author":"Ye","year":"2019","journal-title":"Gynecol Endocrinol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.760430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T05:42:09Z","timestamp":1645076529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.760430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":23,"alternative-id":["10.3389\/fmed.2022.760430"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.760430","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"article-number":"760430"}}